Immunodermatology News

Although systemic sclerosis treatments have often been stymied in clinical development, a trio of “interesting future therapies” may offer new options, according to a presenter at the 2020 Congress of Clinical Rheumatology-East.

Mortality due to systemic sclerosis remains high compared with mortality in the general population, despite a steady decline in mortality rates from 2001 through 2015, according to data published in Arthritis Care & Research.

Botulinum toxin can help improve the quality of life in patients with hidradenitis suppurativa, according to a study.

Hidradenitis suppurativa was associated with an increased overall risk for cancer, as well as an increased risk for several specific cancers, according to a study published in JAMA Dermatology.

Biologic therapies have been proven to significantly change treatment ability and improve the condition of patients with hidradenitis suppurativa, according to a presentation at the Interdisciplinary Autoimmune Summit.

The FDA has expanded approval of Stelara to include the treatment of moderate to severe pediatric plaque psoriasis, Janssen Pharmaceutical announced in a press release.

In patients with varying severity of hidradenitis suppurativa, dapsone, in combination with other therapies, was an effective method of treatment, according to findings presented at the American Academy of Dermatology virtual meeting.

Bruton tyrosine kinase inhibitor rilzabrutinib, in association with longer treatment, showed improved clinical activity in patients with pemphigus, according to a study reported at the American Academy of Dermatology virtual meeting.

A study presented at the American Academy of Dermatology virtual meeting associated several risk factors for herpes zoster hospitalization in those with chronic inflammatory skin diseases.

Kymera Therapeutics has initiated a non-interventional trial evaluating IRAK4 expression in hidradenitis suppurativa and atopic dermatitis, according to a press release.